Purpose: CDK4/6i combined with endocrine therapy have improved HR+/HER2-metastatic breast cancer (MBC) outcomes. However, it is still unclear whether the response to CDK4/6i is similar for all races. Therefore, we aimed to assess overall survival (OS) trends strati ed by race in patients with HR+/HER2-MBC after the approval of CDK4/6i, as part of the standard of care, in 2015.Methods: We performed a population-based study using the SEER database. Patients with HR+/HER2-MBC were divided into two time-based cohorts: 1) 2011-2013, corresponding to the pre-CDK4/6i era, and 2) 2015-2017 to the post-CDK4/6i era. We used propensity score matching and identi ed 2,684 patients in each cohort that matched in several characteristics. Kaplan-Meier curves and Cox proportional hazard models were used to estimate 2-year OS.Additionally, we compared survival between groups with a strati ed log-rank test. Lastly, we compared OS and breast cancer death risk between cohorts (strati ed by race) using Fine and Gray model.
Results:The 2-year OS rate was 65% for the post-CDK4/6i group and 62% for the pre-CDK4/6i cohort (strati ed logrank p=0.025). The 2-year OS for NHW patients improved in the post-CDK4/6i era compared to the pre-CDK4/6i era (67% vs. 63%, p=0.033). However, OS did not improve for NHB (54% vs. 54%, p=0.876) or Hispanic (67% vs 65%, p=0.617) groups.Conclusions: Our study con rms that outcomes for HR+/HER2-MBC have improved after CDK4/6i were introduced in 2015. However, this effect is primarily driven by the improved OS in NHW patients, without signi cant improvement in OS in NHB or Hispanics.
Purpose: CDK4/6i combined with endocrine therapy have improved HR+/HER2- metastatic breast cancer (MBC) outcomes. However, it is still unclear whether the response to CDK4/6i is similar for all races. Therefore, we aimed to assess overall survival (OS) trends stratified by race in patients with HR+/HER2- MBC after the approval of CDK4/6i, as part of the standard of care, in 2015.
Methods: We performed a population-based study using the SEER database. Patients with HR+/HER2- MBC were divided into two time-based cohorts: 1) 2011-2013, corresponding to the pre-CDK4/6i era, and 2) 2015-2017 to the post-CDK4/6i era. We used propensity score matching and identified 2,684 patients in each cohort that matched in several characteristics. Kaplan-Meier curves and Cox proportional hazard models were used to estimate 2-year OS. Additionally, we compared survival between groups with a stratified log-rank test. Lastly, we compared OS and breast cancer death risk between cohorts (stratified by race) using Fine and Gray model.
Results: The 2-year OS rate was 65% for the post-CDK4/6i group and 62% for the pre-CDK4/6i cohort (stratified log-rank p=0.025). The 2-year OS for NHW patients improved in the post-CDK4/6i era compared to the pre-CDK4/6i era (67% vs. 63%, p=0.033). However, OS did not improve for NHB (54% vs. 54%, p=0.876) or Hispanic (67% vs 65%, p=0.617) groups.
Conclusions: Our study confirms that outcomes for HR+/HER2- MBC have improved after CDK4/6i were introduced in 2015. However, this effect is primarily driven by the improved OS in NHW patients, without significant improvement in OS in NHB or Hispanics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.